All In Biotech

Drug Trial Radar · NCT04974151

China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype

Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Participants With Hypertension and MTHFR 677 TT Genotype: A Multi-center, Randomized, Double-blind, Triple-dummy, Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 24,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

24,000

Planned (sponsor's estimate)

Start

Aug 22, 2024

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Shenzhen Ausa Pharmed Co.,LtdIndustry
Sponsor type
Industry
Collaborators
Peking University First Hospital; Second Affiliated Hospital of Nanchang University; The First People's Hospital of Lianyungang; The Affiliated Hospital Of Guizhou Medical University; Lianyungang Oriental Hospital; Tengzhou Central People's Hospital; The First Affiliated Hospital of Bengbu Medical University; Shenzhen Prospective Medical Technology Co., LTD; Weinan Central Hospital; The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine; Loudi Central Hospital; Yancheng First People's Hospital; TAIHE country people's hospital; First Affiliated Hospital of Gannan Medical University; Yangjiang People's Hospital; Deyang People's Hospital; Bozhou people's hospital; Chizhou people's hospital; Lianyungang Second People's Hospital; The Affiliated Hospital Of Southwest Medical University; Chengdu Fifth People's Hospital
First posted
Jul 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype. The study participants will be randomized to one of the three treatment groups: Group A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator. Group B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily. Group C: amlodipine folic acid 5.8mg tablet plus 5-methyltetrahydrofolate (5-MTHF, 0.4mg), taken orally, once daily. The primary endpoint is first ischemic stroke.

Conditions

  • Hypertension
  • MTHFR 677 TT Genotype

Interventions

  • Amlodipine besylateDrug

    The amlodipine used in this study is a listed product.

  • Amlodipine besylate And Folic AcidDrug

    The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.

  • 5-methyltetrahydrofolate (5-MTHF)Drug

    The 5-MTHF used in this study is a listed product.

  • Amlodipine placeboDrug

    Amlodipine placebos are dummy pills of amlodipine with identical appearance.

  • Amlodipine folic acid placeboDrug

    Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.

  • 5-MTHF PlacebosDrug

    5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First ischemic strokeTime frame: By the end of the fifth year of the study

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • First Affillated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • Bozhou People's Hospital

    Bozhou, Anhui, China · Not yet recruiting

  • Chizhou People's Hospital

    Chizhou, Anhui, China · Not yet recruiting

  • Taihe County People's Hospital

    Fuyang, Anhui, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Yangjiang People's Hospital

    Yangjiang, Guangdong, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • The First Affiliated Hospital of Hunan University of Medicine

    Huaihua, Hunan, China · Not yet recruiting

  • Loudi Central Hospital

    Loudi, Hunan, China · Not yet recruiting

  • Lianyungang Oriental Hospital

    Lianyungang, Jiangsu, China · Recruiting

  • The First People's Hospital of Lianyungang

    Lianyungang, Jiangsu, China · Not yet recruiting

  • The Second People's Hospital of Lianyungang

    Lianyungang, Jiangsu, China · Not yet recruiting

  • Yancheng First People's Hospital

    Yancheng, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China · Not yet recruiting

  • Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Weinan Central Hospital

    Weinan, Shaanxi, China · Not yet recruiting

  • Tengzhou Central People's Hospital

    Zaozhuang, Shandong, China · Not yet recruiting

  • Chengdu Fifth People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Deyang People's Hospital

    Deyang, Sichuan, China · Not yet recruiting

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.